DANIPHARM A/S: Financial statements 2022
CVR: 12335040
Source: annual report 2022, Danish Business Authority
01/07/2021 – 30/06/2022
DANIPHARM A/S (CVR 12335040) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK 34,935,080 and a net result of DKK 8,190,711 compared with DKK 2,944,039 the year before. That is an increase of 18.8% compared with the year before. Equity in the 2022 report amounted to DKK 36,059,219. The solvency ratio was 46%. The company had 26 employees in the financial year.
- Gross Profit
- DKK 34,935,080
- Profit/Loss
- DKK 8,190,711
- Equity
- DKK 36,059,219
- Total Assets
- DKK 78,307,232
- Employees
- 26
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | 34.9 mio. | 8.2 mio. | 36.1 mio. | 26 |
| 2021 | - | 29.4 mio. | 2.9 mio. | 29.9 mio. | 25 |
| 2020 | 91.6 mio. | 31.6 mio. | 5.8 mio. | 26.9 mio. | 22 |
| 2019 | - | 42.9 mio. | 16.3 mio. | 21.2 mio. | 21 |
| 2018 | - | 35.7 mio. | 10.2 mio. | 24.8 mio. | 22 |
Official annual report
Keep an eye on DANIPHARM A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout DANIPHARM A/S
DANIPHARM A/S is a Danish company of the type Aktieselskab based in Kastrup, founded in 1988. The company is registered under the industry Fremstilling af farmaceutiske råvarer. The management consists of Peter Rørvig. The board consists of Niels Ulrik Heine (chair), Helle Rørvig and Peter Rørvig. The company is owned by H&P Rørvig Holding A/S. The company has 24 employees (2018). In 2025, the company reported a gross profit of DKK 37,586,751 and a net result of DKK 13,717,304 compared with DKK 5,113,647 the year before. Equity in the 2025 report amounted to DKK 60,280,949.